JAMA dermatology最新文献

{"title":"JAMA+ Trials Editor's Choice for Clinical Trial of 2025 in JAMA Dermatology.","authors":"Kanade Shinkai, John S Barbieri, Alison Huang","doi":"10.1001/jamadermatol.2026.2497","DOIUrl":"10.1001/jamadermatol.2026.2497","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"879"},"PeriodicalIF":10.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Golimumab in Treatment-Refractory Hidradenitis Suppurativa.","authors":"Madeline Sage, Christopher J Sayed","doi":"10.1001/jamadermatol.2026.1457","DOIUrl":"10.1001/jamadermatol.2026.1457","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"956-957"},"PeriodicalIF":10.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13254801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proportion of Antiepileptic Drug-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis.","authors":"Erika Yue Lee, Christopher Knox, Cinthiya Sugumar, Elizabeth Jane Phillips","doi":"10.1001/jamadermatol.2026.2473","DOIUrl":"10.1001/jamadermatol.2026.2473","url":null,"abstract":"<p><strong>Importance: </strong>Antiepileptic drugs (AEDs) are frequently implicated in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are the most severe type of drug hypersensitivity reaction, with a mortality rate up to 50%. However, the overall proportion of these cases attributed to AEDs has not been systematically reviewed.</p><p><strong>Objective: </strong>To evaluate the proportion of AED-associated SJS/TEN.</p><p><strong>Data sources: </strong>The MEDLINE and Embase databases were searched from inception through March 17, 2026, with results limited to English-language publications and human participants.</p><p><strong>Study selection: </strong>All experimental and observational studies that reported patient-level triggers of SJS/TEN were included.</p><p><strong>Data extraction and synthesis: </strong>Two reviewers independently screened studies and extracted data using a predefined template. To estimate the proportion of AED-associated SJS/TEN, a random-effects meta-analysis was performed, calculating the pooled proportions with 95% CIs. Subgroup analyses by age group (children vs adults) and geographic region were performed to explore heterogeneity.</p><p><strong>Main outcomes and measures: </strong>To estimate the proportion of AED-associated SJS/TEN.</p><p><strong>Results: </strong>This systematic review and meta-analysis included 50 studies with 4403 patients that reported patient-level triggers of SJS/TEN. Single-drug triggers accounted for 88% (95% CI, 83-92) of cases. The pooled proportion of SJS/TEN cases attributed to AEDs was 23% (95% CI, 19-26). Nearly all AED-associated cases were due to aromatic AEDs (96%; 95% CI, 92-99), most commonly carbamazepine (39%; 95% CI, 29-50), followed by phenytoin (19%; 95% CI, 11-28), and lamotrigine (15%; 95% CI, 8-22). Nonaromatic AEDs were rarely implicated (2%; 95% CI, 0-4). Significant geographic variation was observed in the proportion of AED-associated SJS/TEN, ranging from 42% (95% CI, 26-59) in West Asia to 10% (95% CI, 0-33) in Africa (P < .001). The proportion of AED-associated SJS/TEN cases was significantly higher in children (35%; 95% CI, 22-48) than in adults (23%; 95% CI, 20-27).</p><p><strong>Conclusions and relevance: </strong>In this systematic review and meta-analysis of observational studies, AEDs accounted for nearly one-quarter of SJS/TEN cases reported worldwide, predominantly involving aromatic AEDs, such as carbamazepine, phenytoin, and lamotrigine. These findings suggest aromatic AEDs as leading contributors to SJS/TEN and support the preferential use of nonaromatic AEDs when clinically appropriate.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"912-921"},"PeriodicalIF":10.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13392837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148549176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postural Orthostatic Tachycardia Syndrome and Dermatomyositis.","authors":"Sarah Jun, Lillian Xie, Lais Lopes Almeida Gomes, Sarini Saksena, Elena Wei, Caroline J Stone, Daniela Forman Faden, Xiwei Yang, Ahmed Eldaboush, Victoria P Werth","doi":"10.1001/jamadermatol.2026.2132","DOIUrl":"10.1001/jamadermatol.2026.2132","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"960-963"},"PeriodicalIF":10.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13373726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148446956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Associated Factors of Intentional Outdoor Tanning Among US Adults.","authors":"Dawn M Holman, Michael A Boring, Anne K Julian, Richard P Moser, Frank M Perna","doi":"10.1001/jamadermatol.2026.2450","DOIUrl":"10.1001/jamadermatol.2026.2450","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Intentional outdoor tanning involves exposing one's skin to UV radiation from the sun for the purpose of darkening the skin to create a tanned appearance. Although robust surveillance data are available on many skin cancer risk factors, limited data on intentional outdoor tanning prevalence have been reported to date.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To examine the prevalence of intentional outdoor tanning among US adults and the factors associated with this behavior.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This cross-sectional study used data from US adults who participated in the 2024 National Health Interview Survey, a nationally representative sample of civilian, noninstitutionalized US adults aged 18 years or older, to assess the prevalence of intentional outdoor tanning and sunburn by asking participants \"when spending time outdoors, how often do you try to get some sun for the purpose of developing a tan?\" (always, most of the time, sometimes, rarely, or never) and \"during the past 12 months, did you have a sunburn even on a small part of your skin?\" (yes or no). The individual-level factors analyzed were demographic characteristics and health-related behaviors, including physical activity and alcohol use.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary outcome was prevalence of intentional outdoor tanning. The secondary outcome was prevalence of sunburn.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 31 615 US adults (mean [SD] age, 48.3 [18.6] years; 17 111 females [51.4%]) were included in the study. Overall, the unadjusted prevalence of intentional outdoor tanning among adults was 30.2% (35.6% [95% CI, 34.6%-36.7%] in women and 26.6% [95% CI, 25.6%-27.7%] in men). Among women and men, prevalence of intentional outdoor tanning was associated with age, race and ethnicity, sun sensitivity, physical activity, and alcohol use. Among women, prevalence was highest among those aged 18 to 29 years (48.1%; 95% CI, 45.3%-50.9%), non-Hispanic White women (41.3%; 95% CI, 39.9%-42.7%), non-sun-sensitive women (38.3%; 95% CI, 36.6%-40.1%), women who met both aerobic and strength guidelines (39.5%; 95% CI, 37.6%-41.5%), and women who engaged in heavy or binge drinking (47.2%; 95% CI, 44.8%-49.7%) (P for all &lt; .001). Among men, prevalence was highest among those aged 18 to 29 years (29.9%; 95% CI, 27.4%-32.6%), non-Hispanic White men (30.5%; 95% CI, 29.0%-32.1%), sun-sensitive men (28.7%; 95% CI, 27.2%-30.2%), men who met both aerobic and strength guidelines (32.2%; 95% CI, 30.2%-34.3%), and men who engaged in heavy or binge drinking (31.2%; 95% CI, 29.0%-33.5%) (P for all &lt; .001). Among women only, prevalence was associated with educational level and body mass index, with a higher prevalence among women with some college (37.5%; 95% CI, 35.8%-39.3%) and those at a healthy weight (38.7%; 95% CI, 37.0%-40.5%; P for all &lt; .001). Among men only, prevalence was associated with marital status, wi","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"904-911"},"PeriodicalIF":10.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13392836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148549114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sweet Syndrome.","authors":"Yi-Shan Teng, Huei-Jing Wang, Yang-Yi Chen","doi":"10.1001/jamadermatol.2026.2457","DOIUrl":"10.1001/jamadermatol.2026.2457","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"950-951"},"PeriodicalIF":10.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148722398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tuberculosis-Related Outcomes in Dermatologic Patients Receiving Systemic Therapy: A Systematic Review and Meta-Analysis.","authors":"Kaixuan Liu, Ziyi Zeng, Wenjie Lu, Yin Yang, Tong Lin","doi":"10.1001/jamadermatol.2026.2365","DOIUrl":"10.1001/jamadermatol.2026.2365","url":null,"abstract":"<p><strong>Importance: </strong>Biologic agents are commonly used with conventional immunosuppressants for treatment of immune-mediated dermatologic diseases, raising concerns about tuberculosis (TB) risk, particularly in high-burden geographic regions. Previous studies have shown inconsistent results across biologic classes, with most focusing on active TB and limited data on latent TB infection (LTBI) conversion.</p><p><strong>Objectives: </strong>To evaluate the incidence of active TB and LTBI conversion in dermatologic patients receiving systemic therapy and to explore differences by biologic class and regional TB burden.</p><p><strong>Data sources: </strong>PubMed/MEDLINE, Embase, Web of Science Core Collection, and the Cochrane Library were searched from database inception to October 1, 2025. Controlled vocabulary and free-text terms were used for dermatologic diseases, systemic therapies, and tuberculosis-related outcomes. Clinical trial registries and reference lists were also screened.</p><p><strong>Study selection: </strong>Randomized clinical trials, cohort studies, case-control studies, and cross-sectional studies reporting active TB or LTBI conversion in dermatologic patients receiving systemic therapy were included. Two reviewers independently screened records and performed full-text assessment.</p><p><strong>Data extraction and synthesis: </strong>Data extraction and risk-of-bias assessment (Newcastle-Ottawa Scale and Cochrane Risk of Bias tool) were conducted independently by 2 reviewers following PRISMA guidelines. Single-arm incidence rates were pooled using random-effects models with logit transformation. Prespecified subgroup analyses were conducted by biologic class and regional TB burden.</p><p><strong>Main outcomes and measures: </strong>Primary outcomes were incidence of LTBI conversion (among patients with negative baseline results of tuberculin skin test or interferon-gamma release assay) and active TB during follow-up.</p><p><strong>Results: </strong>Of 4726 records identified, 31 studies comprising a total of 15 005 patients met inclusion criteria and were included in the analysis. The pooled incidence of LTBI conversion was 4.3%, highest with tumor necrosis factor inhibitors, followed by interleukin (IL)-17 and ustekinumab (IL-12/23 p40 inhibitor). The overall incidence of active TB was 1.0% and it was more frequent in high-burden regions.</p><p><strong>Conclusions and relevance: </strong>In this systematic review and meta-analysis, TB-related risk varied by biologic mechanism and epidemiologic context. Risk assessment and monitoring should integrate dermatologic treatment class and regional TB burden to guide clinical decision-making.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"894-903"},"PeriodicalIF":10.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13373736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148447025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Golidocitinib for Folliculotropic Mycosis Fungoides.","authors":"Xingwei Zhang, Yanjing Chen, Yao Xie, Kexing Ren, Ming Jiang, Liqun Zou, Lin Wang","doi":"10.1001/jamadermatol.2026.1855","DOIUrl":"10.1001/jamadermatol.2026.1855","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"963-965"},"PeriodicalIF":10.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148446943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristic Corkscrew and Comma Hairs in Tinea Capitis.","authors":"Lula María Nieto-Benito, Loreto Carrasco-Santos","doi":"10.1001/jamadermatol.2026.2480","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.2480","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.","authors":"Aaron R Mangold, Anna Haemel, Neda Shahriari, Benjamin Chong, Anthony P Fernandez, David Fiorentino, David Pearson, Jason Sluzevich, Oluwakemi Onajin, Pranita V Rambhatla, Mehdi Rashighi, Charlotte Hurabielle, David Fivenson, Erin Boh, Taraneh Paravar, Ashley Crew, R Hal Flowers, Dustin Taylor, Sweta Subhardashani, Donna Culton, Courtney Schadt, Jeffrey Callen, Christina Lam, Lauren Graham, Kimberly Hashemi, Rochelle Castillo, Andrea Maderal, Scott Elman, Katharina S Shaw, Matthew D Cascino, Avery LaChance, Michelle S Min, Alisa Femia, Ruth Ann Vleugels, Victoria P Werth","doi":"10.1001/jamadermatol.2026.3199","DOIUrl":"10.1001/jamadermatol.2026.3199","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Brepocitinib, a first-in-class oral, selective TYK2 and JAK1 inhibitor, demonstrated broad efficacy in a phase 3 randomized clinical trial in dermatomyositis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the effects of brepocitinib on cutaneous disease activity, itch, skin-related quality of life (QOL), and achievement of remission-level end points in adults with dermatomyositis over 52 weeks of treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This prespecified secondary analysis of the 52-week, phase 3, double-blind, placebo-controlled, randomized VALOR clinical trial, conducted from October 2022 to July 2025 at 90 sites in 20 countries, included adults with dermatomyositis and active skin and muscle disease.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention: &lt;/strong&gt;Once-daily brepocitinib, 30 mg; brepocitinib, 15 mg; or placebo.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Key secondary outcomes in VALOR included change in the Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A) score and achievement of clinically meaningful CDASI-A response (≥40% relative and ≥4-point absolute improvement). Exploratory outcomes included itch (Peak Pruritus Numeric Rating Scale [PP-NRS]); skin-related QOL (Skindex-16); achievement of Cutaneous Dermatomyositis Activity-Investigator's Global Assessment (CDA-IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point improvement; and functional skin remission (CDASI-A ≤5). Between-group differences were analyzed using ANCOVA or Cochran-Mantel-Haenszel methods.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The VALOR trial enrolled 241 participants (mean [SD] age, 50.6 [13.3] years; 187 [77.6%] female; 54 [22.4%] male). Beginning at week 4, brepocitinib, 30 mg, demonstrated superiority over placebo in mean (SD) change from baseline in CDASI-A score (-6.4 [5.8] vs -3.5 [6.0], respectively; difference, -3.0; 95% CI, -4.6 to -1.4; P &lt; .001) and resulted in greater achievement of clinically meaningful CDASI-A response (27 participants [33.3%] vs 14 participants [17.7%], respectively; difference, 15.1 percentage points [pp]; 95% CI, 1.7-28.6 pp), itch remission (PP-NRS ≤1: 31 participants [38.3%] vs 15 participants [19.0%], respectively; difference, 18.9 pp; 95% CI, 5.0-32.9 pp) and improvement in skin-related QOL (Skindex-16 score: -12.9 [21.6] vs -0.9 [22.4], respectively; difference, -11.9; 95% CI, -17.9 to -6.0). Benefits on these measures were observed at all time points from week 4 through week 52. Among the 155 participants (64.3%) with moderate to severe skin disease at baseline, brepocitinib, 30 mg, was also associated with higher rates of achievement of a CDA-IGA score of clear or almost clear compared with placebo (21 participants [45.7%] vs 12 participants [21.8%], respectively; difference, 21.1 pp at week 52; 95% CI, 2.5-39.7 pp) and functional skin remission (20 participants [43.5%] vs 11 participants [20.8%], respectively; difference at week 52, 26.6 ","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}